Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
86.6M
-
Number of holders
-
222
-
Total 13F shares, excl. options
-
101M
-
Shares change
-
-686K
-
Total reported value, excl. options
-
$1.56B
-
Value change
-
+$19.1M
-
Put/Call ratio
-
0.56
-
Number of buys
-
119
-
Number of sells
-
-98
-
Price
-
$15.39
Significant Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q3 2025
272 filings reported holding SNDX - Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share as of Q3 2025.
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) has 222 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 101M shares
.
Largest 10 shareholders include BlackRock, Inc. (8.63M shares), Kynam Capital Management, LP (8.52M shares), GOLDMAN SACHS GROUP INC (5.49M shares), VANGUARD GROUP INC (5.14M shares), Point72 Asset Management, L.P. (4.26M shares), STATE STREET CORP (3.85M shares), BANK OF AMERICA CORP /DE/ (3.7M shares), Eversept Partners, LP (3.47M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.31M shares), and KINGDON CAPITAL MANAGEMENT, L.L.C. (2.5M shares).
This table shows the top 222 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.